The Global Liraglutide Market is estimated to be valued at USD 2.38 Bn in 2025 and is expected to decline to USD 1.58 Bn by 2032, exhibiting a negative compound annual growth rate (CAGR) of -5.6% from 2025 to 2032.
The global liraglutide market, once considered a rapidly expanding segment within the diabetes therapeutics landscape, is now experiencing a phase of gradual deceleration, marked by a negative compound annual growth rate (CAGR). This shift is largely attributed to the evolving dynamics in the diabetes care ecosystem, including increased competition from newer-generation GLP-1 receptor agonists, biosimilars, and combination therapies. Liraglutide, a pioneering GLP-1 receptor agonist known for its dual benefits in type 2 diabetes management and weight reduction, continues to hold clinical relevance due to its established efficacy in improving glycemic control and mitigating obesity-related complications. However, its market share is steadily declining as healthcare providers pivot toward newer agents that offer enhanced cardiovascular outcomes, improved tolerability, and more convenient dosing schedules (e.g., once-weekly vs. daily injections). While liraglutide remains a foundational option, especially in legacy treatment protocols, its position is increasingly being challenged by more advanced alternatives.
Market Dynamics
The global liraglutide market's downturn is caused by multiple converging factors. Chief among these is the emergence of superior GLP-1 analogs and dual/triple agonist therapies, which have demonstrated improved clinical outcomes and patient adherence. As healthcare systems worldwide strive to optimize diabetes treatment strategies, these newer agents are being adopted more rapidly, reducing the demand for liraglutide. Moreover, patent expirations have opened the market to biosimilar competition, further compressing margins for originator manufacturers. High treatment costs remain a deterrent, particularly in low- and middle-income markets, where liraglutide's affordability and accessibility are limited. The stringent regulatory landscape and increasing scrutiny over drug safety and efficacy have also hindered expansion into newer indications and markets.
Despite the negative growth trend, niche opportunities persist. These include its continued use in specific patient subgroups, ongoing clinical research into pediatric and adolescent obesity management, and potential incorporation into combination regimens where its unique pharmacokinetic profile offers added value. Additionally, while market growth is stalling in mature regions like North America and Europe, emerging economies with rising diabetes prevalence still represent incremental demand potential, albeit limited. Advancements in formulation, such as oral delivery or depot injections, could revive interest if positioned appropriately. Overall, while liraglutide’s market trajectory reflects a slowdown, it remains a clinically relevant therapy amidst a rapidly shifting treatment paradigm in diabetes and obesity care.
Key features of the study
Market Segmentation
Market Segmentation
すべてのレポートを無料でカスタマイズ可能です。単独セクションの購入や国別レポートも含まれます。
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
